Colorectal Cancer Coverage from Every Angle

Genetic Variants in Predicting Treatment Outcomes in Colorectal Cancer

By: Cordi Craig
Posted: Friday, March 1, 2019

A presentation at the 2019 Gastrointestinal Cancers Symposium in San Francisco (Abstract 566) suggested that single nucleotide polymorphisms (SNP) in the telomerase complex may help predict first-line treatment outcomes in patients with metastatic colorectal cancer. Francesca Battaglin, MD, of the Instituto Oncologico Veneto, Padova, Italy, and colleagues suggest that these genetic variants may have both a predictive and prognostic value in this patient population.

The authors analyzed the impact of 21 selected SNPs within 13 genes on genomic DNA from 451 patients with metastatic colorectal cancer; they used data from two independent phase III trials: TRIBE and FIRE-3. In the TRIBE study, patients treated with bevacizumab and FOLFIRI (leucovorin, fluorouracil, and irinotecan) served as a discovery cohort (n = 215). In the FIRE-3 trial, patients treated with bevacizumab/FOLFIRI served as the validation cohort (n = 107) and those treated with cetuximab/FOLFIRI served as the control (n = 129).

Patients in the discovery cohort carrying any A allele of TERT rs2075786 achieved longer median progression-free (P = .021) and overall survival (P = .005) than did those carrying the G/G genotype. Similarly, patients carrying any T allele of CLPTM1L rs401681 had better survival than did those with the C/C genotype (P = .022). Patients carrying the C allele of TERC rs2293607 had longer overall survival rates. Extended progression-free survival rates were associated with the presence of the A/A genotype of ACD rs6979. In contrast, in the control cohort, the T/T genotype of CLPTM1L rs401681 was associated with a shorter median progression-free survival.

Disclosure: The study authors’ full disclosures can be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.